title: Teriparatide (PTH 1-34) treatment increases peripheral hematopoietic stem cells in postmenopausal women.
abstract: Cells of the osteoblast lineage play an important role in regulating the hematopoietic stem cell (HSC) niche and early B-cell development in animal models, perhaps via parathyroid hormone (PTH)-dependent mechanisms. There are few human clinical studies investigating this phenomenon. We studied the impact of long-term daily teriparatide (PTH 1-34) treatment on cells of the hematopoietic lineage in postmenopausal women. Twenty-three postmenopausal women at high risk of fracture received teriparatide 20 mcg sc daily for 24 months as part of a prospective longitudinal trial. Whole blood measurements were obtained at baseline, 3, 6, 12, and 18 months. Flow cytometry was performed to identify hematopoietic subpopulations, including HSCs (CD34+/CD45(moderate); ISHAGE protocol) and early transitional B cells (CD19+, CD27-, IgD+, CD24[hi], CD38[hi]). Serial measurements of spine and hip bone mineral density (BMD) as well as serum P1NP, osteocalcin, and CTX were also performed. The average age of study subjects was 64 ± 5 years. We found that teriparatide treatment led to an early increase in circulating HSC number of 40% ± 14% (p = 0.004) by month 3, which persisted to month 18 before returning to near baseline by 24 months. There were no significant changes in transitional B cells or total B cells over the course of the study period. In addition, there were no differences in complete blood count profiles as quantified by standard automated flow cytometry. Interestingly, the peak increase in HSC number was inversely associated with increases in bone markers and spine BMD. Daily teriparatide treatment for osteoporosis increases circulating HSCs by 3 to 6 months in postmenopausal women. This may represent a proliferation of marrow HSCs or increased peripheral HSC mobilization. This clinical study establishes the importance of PTH in the regulation of the HSC niche within humans. © 2014 American Society for Bone and Mineral Research.
authors.affiliation: Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.
authors.forename: Elaine W
authors.initials: EW
authors.lastname: Yu
authors.forename: Ruchit
authors.initials: R
authors.lastname: Kumbhani
authors.forename: Erica
authors.initials: E
authors.lastname: Siwila-Sackman
authors.forename: Michelle
authors.initials: M
authors.lastname: DeLelys
authors.forename: Frederic I
authors.initials: FI
authors.lastname: Preffer
authors.forename: Benjamin Z
authors.initials: BZ
authors.lastname: Leder
authors.forename: Joy Y
authors.initials: JY
authors.lastname: Wu
mesh_terms: D001402:B-Lymphocytes / Q000166:cytology / Q000187:drug effects; D015415:Biomarkers / Q000378:metabolism; D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002452:Cell Count; D019070:Cell Lineage / Q000187:drug effects; D005260:Female; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000187:drug effects; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause / Q000187:drug effects*; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects; D019379:Teriparatide / Q000494:pharmacology*
chemical_list: D015415:Biomarkers; D019379:Teriparatide
keywords: B CELL LYMPHOPOIESIS; HEMATOPOIETIC STEM CELL NICHE; PARATHYROID HORMONE; TERIPARATIDE